NEVVI Medicare utilization intelligence

← back

RICHARDS, DONALDMD NPI 1659313559 Clinician

Medical Oncology · TYLER, TX

Specialty Medical Oncology — from billed Medicare claims
Trained UNIVERSITY OF TEXAS MEDICAL SCHOOL AT SAN ANTONIO — medical school, self-reported to CMS
In practice about 43 years since medical school (class of 1983, self-reported to CMS)
Location TYLER, TX · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 63 codes billed · 65,951 disclosed services (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
TEXAS ONCOLOGY PA
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2023-07

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J1756 Injection, iron sucrose, 1 mg
J1453 Injection, fosaprepitant, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0897 Injection, denosumab, 1 mg
36415 Insertion of needle into vein for collection of blood sample
J2469 Injection, palonosetron hcl, 25 mcg
80053 Blood test, comprehensive group of blood chemicals
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
J1626 Injection, granisetron hydrochloride, 100 mcg
96375 Injection of additional new drug or substance into vein
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J0640 Injection, leucovorin calcium, per 50 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J9190 Injection, fluorouracil, 500 mg
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
J3489 Injection, zoledronic acid, 1 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
G6015 Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
82784 Gammaglobulin (immune system protein) measurement
96417 Administration of additional new drug or substance into vein, 1 hour or less
96415 Administration of chemotherapy into vein, each additional hour
82378 Carcinoembryonic antigen (cea) protein level
96372 Injection of drug or substance under skin or into muscle
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
85007 Microscopic examination for white blood cells with manual cell count
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
J3490 Unclassified drugs
85055 Reticulated (young) platelet measurement
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
71260 Ct scan of chest with contrast
74177 Ct scan of abdomen and pelvis with contrast
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J1454 Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
84153 Psa (prostate specific antigen) measurement, total
71250 Ct scan of chest without contrast
J7030 Infusion, normal saline solution , 1000 cc
G6013 Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96523 Irrigation of implanted venous access drug delivery device
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96361 Infusion into a vein for hydration, each additional hour
84520 Urea nitrogen level to assess kidney function, quantitative
96411 Administration of additional new drug or substance into vein using push technique
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
83615 Lactate dehydrogenase (enzyme) level
74176 Ct scan of abdomen and pelvis without contrast

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.